APA

Takaki S., Kawakami Y., Imamura M., Aikata H., Takahashi S., Ishihara H., Tsuji K., Aimitsu S., Kawakami H., Nakanishi T., Kitamoto M., Moriya T., Satoh K. & Chayama K. (20080422). Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon-alpha and ribavirin. A prospective randomized controlled trial. : Intervirology.

Chicago

Takaki Shintaro, Kawakami Yoshiiku, Imamura Michio, Aikata Hiroshi, Takahashi Shoichi, Ishihara Hiroto, Tsuji Keiji, Aimitsu Shiomi, Kawakami Hiroiku, Nakanishi Toshio, Kitamoto Mikiya, Moriya Takashi, Satoh Kenichi and Chayama Kazuaki. 20080422. Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon-alpha and ribavirin. A prospective randomized controlled trial. : Intervirology.

Harvard

Takaki S., Kawakami Y., Imamura M., Aikata H., Takahashi S., Ishihara H., Tsuji K., Aimitsu S., Kawakami H., Nakanishi T., Kitamoto M., Moriya T., Satoh K. and Chayama K. (20080422). Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon-alpha and ribavirin. A prospective randomized controlled trial. : Intervirology.

MLA

Takaki Shintaro, Kawakami Yoshiiku, Imamura Michio, Aikata Hiroshi, Takahashi Shoichi, Ishihara Hiroto, Tsuji Keiji, Aimitsu Shiomi, Kawakami Hiroiku, Nakanishi Toshio, Kitamoto Mikiya, Moriya Takashi, Satoh Kenichi and Chayama Kazuaki. Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon-alpha and ribavirin. A prospective randomized controlled trial. : Intervirology. 20080422.